ARANESP -(HSA-FREE) SOLUTION

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

DARBEPOETIN ALFA

Pieejams no:

AMGEN CANADA INC

ATĶ kods:

B03XA02

SNN (starptautisko nepatentēto nosaukumu):

DARBEPOETIN ALFA

Deva:

100MCG

Zāļu forma:

SOLUTION

Kompozīcija:

DARBEPOETIN ALFA 100MCG

Ievadīšanas:

INTRAVENOUS

Vienības iepakojumā:

100

Receptes veids:

Prescription

Ārstniecības joma:

HEMATOPOIETIC AGENTS

Produktu pārskats:

Active ingredient group (AIG) number: 0148081005; AHFS:

Autorizācija statuss:

CANCELLED POST MARKET

Autorizācija datums:

2015-08-04

Produkta apraksts

_ARANESP Product Monograph _
_Page 1 of 50 _
PRODUCT MONOGRAPH
PR
ARANESP

(darbepoetin alfa)
Single-use Vials
†
(15, 25, 40, 60, 100, 200, 325, 500 mcg/vial)
SingleJect

Prefilled Syringes
(10, 15
‡
, 20, 30, 40, 50, 60, 80, 100, 130, 150, 200, 250
‡
, 300, 400
‡
, 500 mcg/syringe)
Subcutaneous Injection; Intravenous Injection
Erythropoiesis Regulating Hormone
Amgen Canada Inc.
6775 Financial Drive, Suite 100
Mississauga, Ontario
L5N 0A4
Date of Approval:
September 4, 2013
Submission Control #: 164290
© 2013 Amgen Canada Inc
_ARANESP Product Monograph _
_Page 2 of 50 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
DESCRIPTION...................................................................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
5
ADVERSE REACTIONS
.................................................................................................
12
DRUG INTERACTIONS
.................................................................................................
19
DOSAGE AND ADMINISTRATION
.............................................................................
19
OVERDOSAGE
...............................................................................................................
24
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 25
STORAGE AND STABILITY
.........................................................................................
27
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 27